Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Essential Bruker NMR Trainings 2024
Join Bruker experts online for 1 hour every month in this essential training program designed for NMR Scientists.
Evaluation of TruVivo, an All-Human Hepatocyte Model for Mechanistic DMPK Investigations
Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.
Essential Bruker NMR Trainings 2023
Join Bruker experts online for 1 hour every month in this essential training program designed for NMR Scientists.
#ExpertAnswers: Audrey Dubourg and Gareth Guenigault on the Organ-On-A-Chip Approach
Audrey Dubourg and Gareth Guenigault from CN Bio discuss the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Industry Insights with Crown Bioscience: Targeting T Cells Within the Cancer-Immunity Cycle
In this episode of Industry Insights, Saskia De Man, PhD, Marrit Putker, PhD, and Pirouz Daftarian, PhD, from Crown Bioscience discuss assays and methods for evaluating T cell therapeutics, including organoids, co-cultures, and high content imaging.
Novel Targets for Alzheimer’s Disease Treatment: Medin and PLD3
Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.
#ExpertAnswers: Ejvind Mørtz on Protein Analysis
Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities.
APS Physiology in Disease Modeling and Drug Development Roundtable
Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
Rethink your Impurity Analysis Strategy
In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.
Overcoming Critical Issues in Glioblastoma Multiforme (GBM) Therapeutic Development
This article, originally published on Scientist.com, reviews the current standard of care for glioblastoma multiforme (GBM), challenges in developing accurate preclinical GBM models and effective therapies, and the future of GBM drug discovery.
Intestinal Toxicity Assessment with Patient-Derived Organoids
Dr. Martin Stahl describes the use of patient-derived intestinal organoids to assess the toxicity of potential therapeutic compounds and study barrier function in a human-specific model system.
Syapse Real-World Dialogue: Advancing Patient Care through Real-World Data, Machine Learning, and Systems Biology
Join Drs. Nitin Baliga and Thomas Brown for an in-depth discussion on utilizing real-world data, machine learning, and systems biology for benefiting therapeutic development.
Combination Therapy for Cancer Treatment
The combination of anti-cancer drugs, or combination therapy, has been hailed as a “cornerstone of cancer therapy” since it targets key pathways synergistically, thereby enhancing efficacy compared to monotherapies. This blog takes a look at a recent publication in Nature, which reported the effects of 2025 pairwise drug combinations in breast, colon, and pancreatic cell lines.
Discovering a Novel Therapy for Urinary Tract Infections
Originally published on Scientist.com, this article provides an overview of antimicrobial therapies, antimicrobial resistance, and advantages of in silico methods for drug discovery.
Cell Painting: The Colorful Future of Drug Discovery
A panel Q&A originally published on Scientist.com that introduces cell painting and highlights its value in preclinical and early drug discovery programs.
#ExpertAnswers: Edward LeCluyse and Paul Gallant on a Novel Hepatic Triculture System
Edward LeCluyse and Paul Gallant discuss their novel all-human hepatic triculture system including its benefits and applications.
Alzheimer’s Disease: Recent Research & Therapeutic Advances
A review of Alzheimer's disease pathology, conventional treatments and their limitations, as well as emerging and potential therapies including monoclonal antibodies, metabolic therapies, and stem cell therapies.
A Novel, All-Human Hepatic Triculture System
Join Edward LeCluyse and Paul Gallant as they offer insight into a novel, all-human hepatic triculture and how this unique system addresses the need for a convenient and human-relevant long-term hepatic culture.
Research Technology & Innovation Summits
The 2022 InsideScientific Research Technology & Innovation Summits focus on specific research and therapeutic areas, reviewing how novel technologies and innovative services are advancing discovery in each particular field.
Cutting Edge Conversations 2022
The Cutting Edge Conversations series offers a deep dive into specific research areas and focused insights regarding market-relevant processes from respected firms in the industry.
Cutting Edge Conversations: Addressing Orphan and Rare Diseases
Joseph Zabinski, PhD, MEM, and Jonathan Kish, PhD, MPH, discuss how research groups are working in the realm of orphan and rare diseases.
Essential Bruker NMR Trainings 2022
Join Bruker experts for 1-hour every other week online for this essential training program designed for NMR Scientists.
